ep adj dilut ep
valu usd unless otherwis note
becton dickinson compani
view report revenu adjust ep exceed
expect manag project organ revenu growth acceler
fx weigh report result
mark second quarter combin legaci bd bard
report sale fce y/i
quarter includ medic deliveri solut grow y/i
cc bioscienc increas y/i cc adjust oper margin
came fce adjust fce
oper expens ratio fce
report cash ep fce y/i report y/
currenc neutral basi
learn earn call
call learn manag confid acceler
organ revenu growth increas rbce y/i
compar basi separ impact global tariff expect
minim impact impact ep
impact ep manag capit deploy
strategi continu includ de-lever balanc sheet
next three year tuck-in
understand integr bard go well manag
confid achiev cost synergi target bard consist
hq visit intra-quart hq visit note
share came pressur owe lower-than-
expect adjust ep guid despit increas top-
line guid investor displeas updat adjust
ep manag narrow ep guidanc
increas midpoint howev
print includ adjust ep beat sinc med-tech near all-
time valuat high think order med-tech stock rise
compani need hit trifecta top-lin beat clean bottom-
line beat rais guidanc beat
rais price target maintain sector perform rate rais
pt assign high multipl share reflect
expans peer group time believ close
valuat gap versu peer group owe continu strength
compani top-lin growth new product launch indic
abil cost synergi bard deal
end continu de-lever pt base
price prior trade day market close estimate unless otherwis note
becton dickinson compani
expect perform line peers/sector
believ compani solid outlook larg reflect
acquisit add complementari product portfolio
medic busi posit global
leader medic manag patient safeti
solut expans market like infus
pump autom dispens infect prevent
addit see potenti revenu synergi
carefus deal strong intern presenc
particularli emerg market total sale
emerg market note time
acquisit carefus sale
portfolio limit overlap bard deal give
multi-year cost-cut opportun access bard
temperatur manag product biosurgeri home
care expect bard transact increas
ep growth trajectori mid-teen y/i appear
reason us also expect deal gener
annual pre-tax cost synergi
revenu synergi begin target
annual pre-tax cost synergi assum
reduct bard total cog oper expens vs
carefus
stock perform execut bard
revenue/cost synergi manag continu expect
low-single-digit ep accret bard also
reiter high-single-digit ep accret target
bard line model assum
cost synergi
assum cost synergi weight
heavili toward sg vs cog particularli
near term execut cost synergi crucial
manag guidanc assum annual
oper margin expans separ
potenti upsid may aris tax synergi well
revenu synergi latter could begin
exhibit becton dickinson compani
bloomberg capit market estim upside/downside/target
base case price target base
larg line large-cap md peer group
base case scenario model organ top-lin growth
rang combin compani bdx bard
scenario assum achiev synergi
bard bard organ top-lin growth
rang also assum stand-alone organ
top-lin growth bottom line model
ep growth low-to-mid teen y/i includ bard
upsid scenario assum share could trade
high next month upsid scenario
model organ top-lin growth includ bard
scenario assum achiev synergi
bard bard organ top-lin growth
rang also assum stand-alone organ
top-lin growth bottom line model
ep growth high-teen y/i includ bard
downsid scenario assum share could trade
low next month model organ
top-lin growth rang includ bard
scenario assum meet cost
synergi target rang bard bard organ top-lin
growth slow rang assum revenu
tax synergi bard downsid scenario
bottom line model ep growth double-digit y/i
becton dickinson compani
price target base pro-forma ebitda estim
combin compani bard target ev/ebitda multipl larg line
large-cap md peer group averag expect post strong top-
bottom-lin growth low-to-mid teen y/i next sever year
high leverag post bard deal pro-forma leverag price target
support sector perform rate
risk rate price target
delay and/or declin govern fund and/or capit spend increas competit
compani key market particularli diagnost fluctuat foreign currenc
failur integr acquisit unforeseen chang reimburs practic outcom
on-going lawsuit volatil emerg market unforeseen difficulti implement
compani erp system
becton dickinson co bd lead global supplier safety-engin product
inject infus therapi sampl collect surgeri sharp dispos bd also global
leader clinic flow cytometri strong global presenc microbiolog molecular
test cytolog complet acquisit carefus mid march
acquisit bard late decemb
becton dickinson compani
net incom applic common sharehold
becton dickinson compani
